Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant

View ORCID ProfileGloria D. Chechet, View ORCID ProfileJacob K.P. Kwaga, Joseph Yahaya, View ORCID ProfileAnnette MacLeod, View ORCID ProfileWalt E. Adamson
doi: https://doi.org/10.1101/2021.12.21.21268166
Gloria D. Chechet
1Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Zaria, Nigeria
2Africa Centre of Excellence for Neglected Tropical Diseases and Forensic Biotechnology, Ahmadu Bello University, Zaria, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gloria D. Chechet
Jacob K.P. Kwaga
2Africa Centre of Excellence for Neglected Tropical Diseases and Forensic Biotechnology, Ahmadu Bello University, Zaria, Nigeria
3Department of Veterinary Public Health and Preventive Medicine, Faculty of Veterinary Medicine, Ahmadu Bello University, Zaria, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jacob K.P. Kwaga
Joseph Yahaya
1Department of Biochemistry, Faculty of Life Sciences, Ahmadu Bello University, Zaria, Zaria, Nigeria
2Africa Centre of Excellence for Neglected Tropical Diseases and Forensic Biotechnology, Ahmadu Bello University, Zaria, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annette MacLeod
4Institute of Biodiversity, Life Sciences, and Animal Health, University of Glasgow, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Annette MacLeod
Walt E. Adamson
4Institute of Biodiversity, Life Sciences, and Animal Health, University of Glasgow, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Walt E. Adamson
  • For correspondence: walt.adamson@glasgow.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Nigeria is the most populated country in Africa with an estimated ∼213 million inhabitants. As of November 2021 there have been three waves of SARS-CoV-2 infection in Nigeria but there has been only one seroprevalence survey conducted to assess the proportion of a population that have been infected, which was performed in December 2020 after the first wave of infection. To provide an update on seroprevalence in Nigeria, we conducted survey at one urban site (n=400) and one rural site (n=402) in Kaduna State, Nigeria during October and November 2021 following the third wave of infection. Seroprevalence for the urban and rural sites was 42.5% and 53.5% respectively (mean 48.0%). Symptoms associated with seropositivity were identified for each site. The overall seroprevalence among unvaccinated individuals was 45.4%. The data indicates an infection rate in Kaduna State at least 387 times greater than that derived from cases confirmed by PCR. Extrapolating to the whole of Nigeria, it would suggest there has been at least 96.7 million infections (compared to 206,138 confirmed cases at the time of surveillance). The work presented here will inform public health policy and deployment strategies for testing, treatment, and vaccination in Nigeria, and provide a baseline for SARS-CoV-2 seroprevalence in Nigeria immediately prior to the spread of the Omicron variant.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by the University of Glasgow COVID-19 Researcher Support Scheme.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics committee of Kaduna State Ministry of Health gave approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 27, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant
Gloria D. Chechet, Jacob K.P. Kwaga, Joseph Yahaya, Annette MacLeod, Walt E. Adamson
medRxiv 2021.12.21.21268166; doi: https://doi.org/10.1101/2021.12.21.21268166
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 seroprevalence in Kaduna State, Nigeria during October/November 2021, following three waves of infection and immediately prior to detection of the Omicron variant
Gloria D. Chechet, Jacob K.P. Kwaga, Joseph Yahaya, Annette MacLeod, Walt E. Adamson
medRxiv 2021.12.21.21268166; doi: https://doi.org/10.1101/2021.12.21.21268166

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (162)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (862)
  • Dentistry and Oral Medicine (159)
  • Dermatology (98)
  • Emergency Medicine (251)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8571)
  • Forensic Medicine (4)
  • Gastroenterology (387)
  • Genetic and Genomic Medicine (1756)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1249)
  • Health Policy (622)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (378)
  • Infectious Diseases (except HIV/AIDS) (10317)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1680)
  • Nursing (97)
  • Nutrition (252)
  • Obstetrics and Gynecology (328)
  • Occupational and Environmental Health (451)
  • Oncology (930)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (538)
  • Pharmacology and Therapeutics (254)
  • Primary Care Research (209)
  • Psychiatry and Clinical Psychology (1775)
  • Public and Global Health (3852)
  • Radiology and Imaging (626)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (521)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (191)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)